Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study

被引：0
|
作者：
Christopher F. Bell
Jake Chung
Bernard Rubin
机构：
[1] GSK,US Value Evidence and Outcomes
[2] GSK,Specialty Care, Global Medical Affairs
[3] GSK,US Medical Affairs, Immuno
来源：
Rheumatology and Therapy | 2023年 / 10卷
关键词：
African American ethnicity; Belimumab; Hispanic ethnicity; Real-world data; Systemic lupus erythematosus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：447 / 462
页数：15
相关论文
共 50 条
  • [1] Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study
    Bell, Christopher F.
    Chung, Jake
    Rubin, Bernard
    RHEUMATOLOGY AND THERAPY, 2023, 10 (02) : 447 - 462
  • [2] Correction: Real-World Clinical Outcomes in Belimumab-Treated US African American and Hispanic Patients with Systemic Lupus Erythematosus: A Retrospective, Observational Study
    Christopher F. Bell
    Jake Chung
    Bernard Rubin
    Rheumatology and Therapy, 2024, 11 (1) : 219 - 219
  • [3] Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study
    Jin, Hui-Zhi
    Cai, Ming-Long
    Wang, Xin
    Li, Zhijun
    Ma, Bin
    Niu, Lin
    Wang, Peng
    Pan, Hai-feng
    Li, Si-dong
    Bao, Wei
    Wang, Guo-sheng
    Li, Xiao-mei
    Xie, Changhao
    Chen, Zhu
    CLINICAL RHEUMATOLOGY, 2025, 44 (01) : 247 - 256
  • [4] Telitacicept versus Belimumab for Patients with Active Systemic Lupus Erythematosus: A Retrospective, Multicenter, Real-world Observational Study
    Chen, Zhu
    Jin, Huizhi
    Li, Yujing
    Wang, Guosheng
    Li, Xiaomei
    Li, Zhijun
    Niu, Lin
    Pan, Haifeng
    ARTHRITIS & RHEUMATOLOGY, 2023, 75 : 4648 - 4650
  • [5] Real-World Effectiveness of Intravenous Belimumab on Clinical Outcomes in Patients With Systemic Lupus Erythematosus in Saudi Arabia : The OBSErve Observational Study
    Al-Homood, Ibrahim Abdulrazag
    Almaghlouth, Ibrahim
    Asiri, Alhussain Mohammed
    Hamdy, Hanan
    Alhammad, Ali
    Mustafa, Alaa
    Othman, Mohamed
    Khamashta, Munther
    Elfishawy, Tamer
    Teichman, Lindsey
    dos Santos, Debora
    Queiroz, Juliana Domenico
    Noibi, Saeed
    OPEN ACCESS RHEUMATOLOGY-RESEARCH AND REVIEWS, 2025, 17 : 33 - 45
  • [6] Use of belimumab in treating patients with systemic lupus erythematosus: a single-center, real-world retrospective study
    Su, Zhaohui
    Zhang, Chunyi
    Gao, Congcong
    Li, Chaoying
    Li, Ruxv
    Zheng, Zhaohui
    ARTHRITIS RESEARCH & THERAPY, 2024, 26 (01)
  • [7] Efficacy and safety of belimumab in patients with lupus nephritis: a real-world retrospective observational study
    Lin, Sishi
    Zhang, Ji
    You, Xiaohan
    Chen, Bo
    Liang, Yan
    Zhou, Yin
    Ding, Xiaokai
    Lv, Yinqiu
    Zhang, Huidi
    Su, Bofeng
    Bai, Yongheng
    Chen, Chaosheng
    RHEUMATOLOGY, 2024, 64 (02) : 614 - 622
  • [8] Evaluating the Use of Glucocorticoids Among Belimumab-Treated Patients With Systemic Lupus Erythematosus in Real-World Settings Using the Rheumatology Informatics System for Effectiveness Registry
    Hammam, Nevin
    Evans, Michael
    Bell, Christopher F.
    Gairy, Kerry
    Yazdany, Jinoos
    Schmajuk, Gabriela
    ACR OPEN RHEUMATOLOGY, 2022, 4 (10) : 883 - 889
  • [9] Effectiveness and safety of belimumab in patients with systemic lupus erythematosus in a real-world setting
    Anjo, C.
    Mascaro, J-M, Jr.
    Espinosa, G.
    Cervera, R.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2019, 48 (06) : 469 - 473
  • [10] COVID-19 in Systemic Lupus Erythematosus patients treated with belimumab: a retrospective clinical study
    Wu, Yinlan
    Li, Yanhong
    Wu, Tong
    Huang, Deying
    Wu, Jianhong
    Zhang, Weihua
    Jiang, Xuejun
    Yao, Chaoqiong
    Liang, Xiuping
    Cheng, Lu
    Liao, Zehui
    Xu, Fang
    Tan, Chunyu
    Liu, Yi
    Herrmann, Martin
    IMMUNOLOGIC RESEARCH, 2024, 72 (03) : 418 - 429
12345